DUNDR, Pavel, Michaela BÁRTŮ, Tjalling BOSSE, Quang Hiep BUI, David CIBULA, Jana DROZENOVÁ, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan HOJNÝ, Nikola HÁJKOVÁ, Radek JAKŠA, Jan LACO, Sigurd F. LAX, Radoslav MATĚJ, Gábor MÉHES, Romana MICHÁLKOVÁ, Adam ŠAFANDA, Kristýna NĚMEJCOVÁ, Naveena SINGH, Simona STOLNICU, Marián ŠVAJDLER, Tomáš ZIMA, Ivana STRUŽINSKÁ a W Glenn MCCLUGGAGE. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. Modern Pathology. NEW YORK: ELSEVIER SCIENCE INC, 2023, roč. 36, č. 1, s. 1-14. ISSN 0893-3952. Dostupné z: https://dx.doi.org/10.1016/j.modpat.2022.100040.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories
Autoři DUNDR, Pavel (203 Česká republika, garant), Michaela BÁRTŮ (203 Česká republika), Tjalling BOSSE, Quang Hiep BUI, David CIBULA (203 Česká republika), Jana DROZENOVÁ (203 Česká republika), Pavel FABIAN (203 Česká republika), Oluwole FADARE, Jitka HAUSNEROVÁ (203 Česká republika, domácí), Jan HOJNÝ (203 Česká republika), Nikola HÁJKOVÁ (203 Česká republika), Radek JAKŠA (203 Česká republika), Jan LACO (203 Česká republika), Sigurd F. LAX, Radoslav MATĚJ (203 Česká republika), Gábor MÉHES, Romana MICHÁLKOVÁ (203 Česká republika), Adam ŠAFANDA (203 Česká republika), Kristýna NĚMEJCOVÁ (203 Česká republika), Naveena SINGH, Simona STOLNICU, Marián ŠVAJDLER (203 Česká republika), Tomáš ZIMA (203 Česká republika), Ivana STRUŽINSKÁ (203 Česká republika) a W Glenn MCCLUGGAGE.
Vydání Modern Pathology, NEW YORK, ELSEVIER SCIENCE INC, 2023, 0893-3952.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30109 Pathology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 7.500 v roce 2022
Kód RIV RIV/00216224:14110/23:00130743
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.modpat.2022.100040
UT WoS 000982550100001
Klíčová slova anglicky borderline; diagnostic agreement; mucinous tumors; next-generation sequencing; ovary; therapeutic targets
Štítky 14110230, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 11. 7. 2023 10:41.
Anotace
Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. We analyzed 124 primary ovarian mucinous tumors originally diagnosed as mucinous borderline tumors (MBTs) or mucinous carcinomas (MCs), with an emphasis on interobserver diagnostic agreement and the potential for diagnostic support by molecular profiling using a next-generation sequencing targeted panel of 727 DNA and 147 RNA genes. Fourteen experienced pathologists independently assigned a diagnosis from preset options, based on a review of a single digitized slide from each tumor. After excluding 1 outlier participant, there was a moderate agreement in diagnosing the 124 cases when divided into 3 categories (κ = 0.524, for mucinous cystadenoma vs MBT vs MC). A perfect agreement for the distinction between mucinous cystadenoma/MBT as a combined category and MC was found in only 36.3% of the cases. Differentiating between MBTs and MCs with expansile invasion was particularly problematic. After a reclassification of the tumors into near-consensus diagnostic categories on the basis of the initial participant results, a comparison of molecular findings between the MBT and MC groups did not show major and unequivocal differences between MBTs and MCs or between MCs with expansile vs infiltrative pattern of invasion. In contrast, HER2 overexpression or amplification was found only in 5.3% of MBTs and in 35.3% of all MCs and in 45% of MCs with expansile invasion. Overall, HER2 alterations, including mutations, were found in 42.2% of MCs. KRAS mutations were found in 65.5% and PIK3CA mutations in 6% of MCs. In summary, although the diagnostic criteria are well-described, diagnostic agreement among our large group of experienced gynecologic pathologists was only moderate. Diagnostic categories showed a molecular overlap. Nonetheless, molecular profiling may prove to be therapeutically beneficial in advanced-stage, recurrent, or metastatic MCs.
Návaznosti
90125, velká výzkumná infrastrukturaNázev: BBMRI-CZ III
VytisknoutZobrazeno: 3. 5. 2024 13:05